166 related articles for article (PubMed ID: 25906750)
1. FKBPL: a marker of good prognosis in breast cancer.
Nelson L; McKeen HD; Marshall A; Mulrane L; Starczynski J; Storr SJ; Lanigan F; Byrne C; Arthur K; Hegarty S; Ali AA; Furlong F; McCarthy HO; Ellis IO; Green AR; Rakha E; Young L; Kunkler I; Thomas J; Jack W; Cameron D; Jirström K; Yakkundi A; McClements L; Martin SG; Gallagher WM; Dunn J; Bartlett J; O'Connor D; Robson T
Oncotarget; 2015 May; 6(14):12209-23. PubMed ID: 25906750
[TBL] [Abstract][Full Text] [Related]
2. FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
McKeen HD; Byrne C; Jithesh PV; Donley C; Valentine A; Yakkundi A; O'Rourke M; Swanton C; McCarthy HO; Hirst DG; Robson T
Cancer Res; 2010 Feb; 70(3):1090-100. PubMed ID: 20103631
[TBL] [Abstract][Full Text] [Related]
3. Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.
Donley C; McClelland K; McKeen HD; Nelson L; Yakkundi A; Jithesh PV; Burrows J; McClements L; Valentine A; Prise KM; McCarthy HO; Robson T
Oncogene; 2014 Jun; 33(26):3441-50. PubMed ID: 23912458
[TBL] [Abstract][Full Text] [Related]
4. FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.
Yakkundi A; Bennett R; Hernández-Negrete I; Delalande JM; Hanna M; Lyubomska O; Arthur K; Short A; McKeen H; Nelson L; McCrudden CM; McNally R; McClements L; McCarthy HO; Burns AJ; Bicknell R; Kissenpfennig A; Robson T
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):845-54. PubMed ID: 25767277
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL.
McKeen HD; Brennan DJ; Hegarty S; Lanigan F; Jirstrom K; Byrne C; Yakkundi A; McCarthy HO; Gallagher WM; Robson T
Biochem Soc Trans; 2011 Apr; 39(2):663-8. PubMed ID: 21428958
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein.
Robson T; James IF
Drug Discov Today; 2012 Jun; 17(11-12):544-8. PubMed ID: 22265918
[TBL] [Abstract][Full Text] [Related]
7. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
[TBL] [Abstract][Full Text] [Related]
8. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
9. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
[TBL] [Abstract][Full Text] [Related]
10. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.
Kimbung S; Kovács A; Bendahl PO; Malmström P; Fernö M; Hatschek T; Hedenfalk I
Mol Oncol; 2014 Feb; 8(1):119-28. PubMed ID: 24287398
[TBL] [Abstract][Full Text] [Related]
11. FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
Annett S; Moore G; Short A; Marshall A; McCrudden C; Yakkundi A; Das S; McCluggage WG; Nelson L; Harley I; Moustafa N; Kennedy CJ; deFazio A; Brand A; Sharma R; Brennan D; O'Toole S; O'Leary J; Bates M; O'Riain C; O'Connor D; Furlong F; McCarthy H; Kissenpfennig A; McClements L; Robson T
Br J Cancer; 2020 Feb; 122(3):361-371. PubMed ID: 31772325
[TBL] [Abstract][Full Text] [Related]
12. Low-frequency nonsynonymous variants in FKBPL and ARPC1B genes are associated with breast cancer risk in Chinese women.
Zhou W; Jiang Y; Zhu M; Hang D; Chen J; Zhou J; Dai J; Ma H; Hu Z; Jin G; Sha J; Shen H
Mol Carcinog; 2017 Feb; 56(2):774-780. PubMed ID: 27479355
[TBL] [Abstract][Full Text] [Related]
13. The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.
Yakkundi A; McCallum L; O'Kane A; Dyer H; Worthington J; McKeen HD; McClements L; Elliott C; McCarthy HO; Hirst DG; Robson T
PLoS One; 2013; 8(2):e55075. PubMed ID: 23457460
[TBL] [Abstract][Full Text] [Related]
14. A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling.
McKeen HD; McAlpine K; Valentine A; Quinn DJ; McClelland K; Byrne C; O'Rourke M; Young S; Scott CJ; McCarthy HO; Hirst DG; Robson T
Endocrinology; 2008 Nov; 149(11):5724-34. PubMed ID: 18669603
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
[TBL] [Abstract][Full Text] [Related]
16. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.
Reijm EA; Timmermans AM; Look MP; Meijer-van Gelder ME; Stobbe CK; van Deurzen CHM; Martens JWM; Sleijfer S; Foekens JA; Berns PMJJ; Jansen MPHM
Ann Oncol; 2014 Nov; 25(11):2185-2190. PubMed ID: 25193989
[TBL] [Abstract][Full Text] [Related]
17. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
18. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
Yu KD; Wu J; Shen ZZ; Shao ZM
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
20. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
